Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis
Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
N/A N=15 Human Papillomatosis Genotyping of Children in Thailand
Recurrent Laryngeal Papillomatosis · Human Papilloma Virus
Primary: Human Papillomavirus Genotypes — 6; 9 participants
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57
Phase 2 N=13 Avelumab for People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
Phase 2 N=32 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants
N/A N=278 Transoral Robotic Surgery for rECurrent Tumours of the Upper Aerodigestive Tract
Recurrent Head and Neck Cancer
Primary: Disease-free Survival at 2 Years — 111 Participants
N/A N=20 Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Phase 3 N=52 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Genital Warts
Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants
N/A N=47 Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia
Vulvar Intraepithelial Neoplasia (VIN)
Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants
N/A N=12 Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
N/A N=32 The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
HIV Positive · Anal Condylomata · Anal Warts
Primary: The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups. — 1; 1 participants
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
N/A N=1 Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Relapsing Polychondritis
Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
N/A N=43 Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
Gastroesophageal Reflux · Laryngopharyngeal Reflux
Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
N/A N=96 Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
Recurrent Pterygium
Primary: Recurrence — 46; 34; 0; 3 eyes — p=<0.05
Phase 2 N=14 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi´s Sarcoma
Primary: Number of Participants With Complete Response — 1; 3 participants
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
Phase 4 N=38 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
Larynx Disease · Gastroesophageal Reflux
Primary: Number of Patients With Dilation of Intracellular Spaces 3 Months After Therapy — 0 participants
N/A N=100 Evaluation of Video Laryngoscopy in Patients With Head and Neck Pathology
Difficult Intubation
Primary: Number of Participants With Cormack-Lehane Grade >2 Obtained With CMAC D Blade — 37 Participants
N/A N=39 A Novel Approach for Thyroplasty Type 1, With Prolene Mesh. A Prospective Study.
Vocal Cord Paralysis · Phonasthenia · Presbylarynges
Primary: Change in Mean Phonation Time — 7.74; 14.08 seconds
N/A N=8 Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants